Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients

Figure 1 The hemoglobin decline in CC and non-CC inosine triphosphate pyrophosphatase genotypes. The hemoglobin (Hb) levels of the CC group show greater decline than those of the non-CC treatment groups during the course of treatment, with significance at weeks 2, 4, 8, 12, 24 and 30. ^aP < 0.05 vs non-CC. The error bars indicate SE of the mean Hb level.

Figure 2 Patients with hemoglobin decline more than 3 g/dL. The percentage of CC and non-CC group patients who had hemoglobin (Hb) decline of more than 3 g/dL during the first 12 wk.

Figure 3 Patients with ribavirin dose reduction. Percentage of patients who had ribavirin (RBV) dose reduction during the first 12 wk of the combination treatment: It was significantly higher in the CC than in the non-CC genotype groups.

Figure 4 Decline of platelets of patients with different inosine triphosphate pyrophosphatase genotypes. The percentages of platelet decline of CC and non-CC group patients throughout the 48 wk of combination treatment. It indicates a greater decline of platelet count in the non-CC than CC variants. ^aP < 0.05 at weeks 12, 24 and 48. Error bars indicate standard error.

Figure 5 Patients with 3 different levels of platelet decline. The percentages of patients according to 3 different levels of platelet decline at week 4 of combination treatment in both groups of inosine triphosphate pyrophosphatase genotypes. Statistical significance is shown with greater level of platelet decline.

Figure 6 White blood cell decline of both inosine triphosphate pyrophosphatase genotypes. The change in white blood cells (WBCs) in the CC and non-CC inosine triphosphate pyrophosphatase genotype groups during the 48 wk of combination treatment: No significant difference between the 2 groups was found. Error bars indicate standard error.